Home > Quotes > ICPT
ICPT

Intercept Pharmaceuticals, Inc. Common Stock Quote & Summary Data

$150.74
*  
2.94
1.91%
Get ICPT Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading ICPT now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Intercept Pharmaceuticals, Inc. Common Stock Intraday Chart




News for ICPT

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 155.50 $ 314.88
Low $ 149.26 $ 89.76

The current last sale of $150.74 is 67.94% Higher thanthe 52 week low.

P/E Ratio

ETFs with ICPT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0% BioShares Biotechnology Clinical Trials Fund (BBC) -9.68 (-32.21%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. Our lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR, which we believe has broad liver-protective properties. OCA has been tested in five placebo-controlled clinical trials, including a Phase 3 clinical trial in patients with primary biliary cirrhosis, recently renamed primary biliary cholangitis, or PBC, and two Phase 2 clinical trials in patients with nonalcoholic fatty liver disease, or NAFLD, and nonalcoholic steatohepatitis, or NASH.  ... More ...  

Risk Grade

Where does ICPT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?